The National Cancer Institute is interested in collaborative research to co-develop, evaluate, or commercialize p53, tumor apoptosis, and HER2 as markers for anti-angiogenesis therapy.
Researchers at the National Cancer Institute have identified tumor cell apoptosis, p53, and HER2 as having potential predictive significance for treatment outcome in breast cancer patients who received anti-angiogenesis therapy in combination with chemotherapy. The researchers have developed a quantitative antibody-based testing method for correlating expression of p53 and HER2 and tumor apoptosis with clinical outcome. These markers can be potentially applied to predict which patients should receive anti-angiogenesis therapy plus chemotherapy.
- A diagnostic kit for predicting benefit of anti-angiogenesis therapy plus chemotherapy in breast cancer patients.
- A testing service for breast cancer patients.
- The clinical predictive markers p53, HER2 and tumor apoptosis indicators are easily and readily evaluated using the new assay.
- New assay potentially useful to determine which patients should or should not receive anti-angiogenesis therapy plus chemotherapy for longer survival and progression-free survival in patients with breast cancer.
- A large, randomized follow-up study will be planned by the inventors and potential collaborators.
Sherry Yang (NCI), Seth M Steinberg (NCI)
- U.S. Patent Filed: U.S. Patent Application Number 14/002,455, Filed 18 Nov 2013
- Foreign Filed: Foreign Filed - Patent Application PCT/US2012/027283, Filed 01 Mar 2012